We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01682473
First Posted: September 11, 2012
Last Update Posted: July 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Zenyaku Kogyo Co., Ltd.
September 4, 2012
September 11, 2012
July 6, 2017
September 20, 2012
April 2, 2015   (Final data collection date for primary outcome measure)
Number of participants with dose-limiting toxicities [ Time Frame: 28 days ]
Same as current
Complete list of historical versions of study NCT01682473 on ClinicalTrials.gov Archive Site
Pharmacokinetics (Cmax, tmax, t½, AUC) [ Time Frame: 28 days ]
Same as current
Not Provided
Not Provided
 
A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
To evaluate the safety (adverse events and dose-limiting toxicity) of daily oral doses of ZSTK474 in patients with advanced solid malignancies.
Open-label, uncontrolled, serial cohort, dose-escalation study evaluating two different dosing regimens (Arm 1: cycles of 5 days on drug and 2 days off drug), Arm 2: cycles of 21 days on drug and 7 days off drug).
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Neoplasms
Drug: ZSTK474
Two arms, each with serial cohorts receiving escalating doses.
  • Experimental: Arm 1: 5/2 Dosing
    Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 5 days on drug and 2 days off drug.
    Intervention: Drug: ZSTK474
  • Experimental: Arm 2: 21/7 Dosing
    Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 21 days on drug and 7 days off drug.
    Intervention: Drug: ZSTK474
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
April 20, 2015
April 2, 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Japanese males or females >= 20 years old
  • Advanced (metastatic or unresectable) solid tumor
  • ECOG performance status score of 0 or 1 and expected survival >12 weeks
  • Recovered from hematological toxicities of prior cancer therapies

Exclusion Criteria:

  • Previous treatment with PI3K inhibitor
  • Serious/significant illnesses or underlying conditions, including diabetes or hepatic renal or CV disease.
  • Other investigational agent within previous 4 weeks
  • Participating in another clinical study
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01682473
ZSTK474-201
Yes
Not Provided
Not Provided
Zenyaku Kogyo Co., Ltd.
Zenyaku Kogyo Co., Ltd.
Not Provided
Principal Investigator: Toshihiko Doi, MD, PhD National Cancer Center Hospital East
Principal Investigator: Shunji Takahashi, MD The Cancer Institute Hospital of JFCR
Zenyaku Kogyo Co., Ltd.
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP